Touchlight, a leader in synthetic DNA technology, has appointed Will Downie as a key adviser to support its mission of advancing genetic medicines. Johnny Ohlson, Founder of Touchlight, said, “Will has significant experience in the pharma services sector, and he will provide valuable insights and connectivity to our team in establishing Touchlight’s synthetic DNA platforms and their key role in the advancement of genetic medicines.” Experience Downie brings a wealth of expertise f...